SCHEMBL1882121

SCHEMBL1882121

COc1ccc2nc(-c3ccccc3)c(CBr)cc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.51
ALDH1A1 P00352 4/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
LMNA P02545 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
GPBAR1 Q8TDU6 2/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
MAPK1 P28482 2/20 0.48
TP53 P04637 2/20 0.48
HPGD P15428 2/20 0.48
TSHR P16473 2/20 0.48
HSD17B10 Q99714 2/20 0.48
MAPT P10636 2/20 0.48
RECQL P46063 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
PKM P14618 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1886186 0.86 KDM4E (0.51) KDM4EALDH1A1L3MBTL1LMNANPSR1
SCHEMBL1891795 0.81 KDM4E (0.57) KDM4EALDH1A1L3MBTL1LMNATDP1
SCHEMBL28539187 0.81 PDE10A (0.65) KDM4EALDH1A1L3MBTL1LMNANPSR1
SCHEMBL1879174 0.79 PDE10A (0.56) KDM4EALDH1A1L3MBTL1LMNANPSR1
SCHEMBL8699704 0.78 KDM4E (0.55) KDM4EALDH1A1L3MBTL1LMNANPSR1
SCHEMBL17942735 0.78 KDM4E (0.55) KDM4EALDH1A1L3MBTL1LMNANPSR1
SCHEMBL6690711 0.78 ERBB2 (0.43) KDM4EALDH1A1L3MBTL1TDP1MAPT
SCHEMBL6788980 0.78 NCF1 (0.46) KDM4EALDH1A1L3MBTL1LMNANPSR1
Bromide SCHEMBL3657824 0.76 PDE10A (0.53) KDM4EALDH1A1L3MBTL1LMNATDP1
SCHEMBL31070199 0.76 KDM4E (0.74) KDM4EALDH1A1L3MBTL1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed
EP-2231641-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2010-09-29 EP disclosed
WO-2009081105-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE KDM4E 2230/4885ALDH1A1 4276/4885L3MBTL1 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.